CJC-1295 (No DAC) + GHRP-6

Buy CJC-1295 (No DAC) + GHRP-6 Online

CJC-1295 (No DAC) + GHRP-6 combines a GHRH-related peptide with a growth hormone secretagogue. The combination is designed around complementary pathways involved in stimulating growth hormone release.

Product Information

CJC-1295 No DAC is generally described as a shorter-acting GHRH analogue, while GHRP-6 activates the growth hormone secretagogue receptor. Human studies have demonstrated that GHRP-6 can strongly stimulate GH release and that GHRP-6 and GHRH can produce synergistic GH responses. However, clinical evidence for this exact CJC-1295 No DAC combination is limited.

How It Works

CJC-1295 No DAC is intended to stimulate the GHRH pathway, while GHRP-6 activates the growth hormone secretagogue receptor. These pathways can converge at the pituitary to increase GH secretion.

POTENTIAL BENEFITS

1. Growth Hormone Research

GHRP-6 has demonstrated strong GH-secretagogue activity in human research. This makes the combination relevant to experiments examining controlled stimulation of the GH axis.

2. GHRH & Secretagogue Interaction

Human studies have shown that GHRH and GHRP-6 can produce a synergistic increase in GH secretion. This provides the biological rationale for studying complementary stimulation of the two pathways.

3. IGF-1 Research

Growth hormone is an important upstream regulator of IGF-1 production. Research involving GH secretagogues therefore provides a useful model for studying downstream GH/IGF-1 signaling.

4. Pituitary-Endocrine Research

The combination allows researchers to examine interactions between GHRH signaling and secretagogue-receptor activation. This can help characterize how different GH-stimulating pathways influence pituitary responses.

Dosage

There is no established clinical dosage for CJC-1295 No DAC + GHRP-6. Human studies of GHRP-6 have used protocols including 1 microgram/kg intravenously, while clinical CJC-1295 studies have involved different formulations and doses. These component-specific protocols should not be treated as a validated dose for the combination.

Side Effects

Potential concerns include headache, flushing, appetite changes, fluid retention, and alterations in glucose or other endocrine pathways. The long-term safety profile of the exact combination remains insufficiently characterized.

References

1. GHRP-6 requires endogenous GHRH for maximal GH stimulation — PubMed
2. GHRP-6 and GHRH effects on GH secretion — PubMed
3. GHRP-6 + GHRH synergistic GH response — PubMed
4. CJC-1295 human pharmacology — PubMed
5. CJC-1295 and GH pulsatility — PubMed

Note: BehemothLabz does not sell this product. Purchase links on this page may direct you to third-party suppliers through affiliate links.

Please click here to see how purchases actually work on this site.